| Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)–positive breast cancer after prior HER2 … HA Burris III, HS Rugo, SJ Vukelja, CL Vogel, RA Borson, S Limentani, ... Journal of Clinical Oncology 29 (4), 398-405, 2011 | 848 | 2011 |
| Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer IE Krop, M Beeram, S Modi, SF Jones, SN Holden, W Yu, S Girish, ... J Clin Oncol 28 (16), 2698-2704, 2010 | 691 | 2010 |
| Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2–positive cancer PM LoRusso, D Weiss, E Guardino, S Girish, MX Sliwkowski Clinical Cancer Research 17 (20), 6437-6447, 2011 | 532 | 2011 |
| A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer who were previously treated with … IE Krop, P LoRusso, KD Miller, S Modi, D Yardley, G Rodriguez, ... Journal of clinical oncology 30 (26), 3234-3241, 2012 | 411 | 2012 |
| Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer S Girish, M Gupta, B Wang, D Lu, IE Krop, CL Vogel, HA Burris III, ... Cancer chemotherapy and pharmacology 69 (5), 1229-1240, 2012 | 293 | 2012 |
| Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion JS Powell, MV Ragni, GC White, JM Lusher, C Hillman-Wiseman, ... Blood 102 (6), 2038-2045, 2003 | 277 | 2003 |
| Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability KA Poon, K Flagella, J Beyer, J Tibbitts, S Kaur, O Saad, JH Yi, S Girish, ... Toxicology and applied pharmacology 273 (2), 298-313, 2013 | 207 | 2013 |
| Personalized cancer vaccines: Clinical landscape, challenges, and opportunities CS Shemesh, JC Hsu, I Hosseini, BQ Shen, A Rotte, P Twomey, S Girish, ... Molecular Therapy, 2020 | 188 | 2020 |
| Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1) H Uppal, E Doudement, K Mahapatra, WC Darbonne, D Bumbaca, ... Clinical Cancer Research 21 (1), 123-133, 2015 | 187 | 2015 |
| Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism BQ Shen, D Bumbaca, O Saad, Q Yue, C V Pastuskovas, ... Current drug metabolism 13 (7), 901-910, 2012 | 141 | 2012 |
| Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma M Stroh, H Winter, M Marchand, L Claret, S Eppler, J Ruppel, O Abidoye, ... Clinical Pharmacology & Therapeutics 102 (2), 305-312, 2017 | 137 | 2017 |
| A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer M Beeram, IE Krop, HA Burris, SR Girish, W Yu, MW Lu, SN Holden, ... Cancer 118 (23), 5733-5740, 2012 | 120 | 2012 |
| A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2 … BC Bender, F Schaedeli-Stark, R Koch, A Joshi, YW Chu, H Rugo, IE Krop, ... Cancer chemotherapy and pharmacology 70 (4), 591-601, 2012 | 93 | 2012 |
| Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors S Ramurthy, S Subramanian, M Aikawa, P Amiri, A Costales, J Dove, ... Journal of medicinal chemistry 51 (22), 7049-7052, 2008 | 92 | 2008 |
| Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical … D Lu, S Girish, Y Gao, B Wang, JH Yi, E Guardino, M Samant, M Cobleigh, ... Cancer chemotherapy and pharmacology 74 (2), 399-410, 2014 | 82 | 2014 |
| Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2‐targeted antibody‐drug conjugate, in … M Gupta, PM LoRusso, B Wang, JH Yi, HA Burris III, M Beeram, S Modi, ... The Journal of Clinical Pharmacology 52 (5), 691-703, 2012 | 82 | 2012 |
| Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting KM Morrissey, M Marchand, H Patel, R Zhang, B Wu, HP Chan, A Mecke, ... Cancer chemotherapy and pharmacology 84 (6), 1257-1267, 2019 | 74 | 2019 |
| Population pharmacokinetics of bevacizumab in cancer patients with external validation K Han, T Peyret, M Marchand, A Quartino, NH Gosselin, S Girish, ... Cancer chemotherapy and pharmacology 78 (2), 341-351, 2016 | 72 | 2016 |
| A model of overall survival predicts treatment outcomes with atezolizumab versus chemotherapy in non–small cell lung cancer based on early tumor kinetics L Claret, JY Jin, C Ferté, H Winter, S Girish, M Stroh, P He, M Ballinger, ... Clinical Cancer Research 24 (14), 3292-3298, 2018 | 67 | 2018 |
| Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor S Ramanathan-Girish, J McColm, JM Clements, P Taupin, S Barrowcliffe, ... Antimicrobial agents and chemotherapy 48 (12), 4835-4842, 2004 | 60 | 2004 |
